Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term rollover study of atacicept in IgA nephropathy
2024-516380-81-00Phase 2Authorised
- Sponsor
- Vera Therapeutics
- Start
- Feb 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 2, open-label trial of atacicept in IgA nephropathy (IgAN) (2 arms), sponsored by Vera Therapeutics. Primary endpoint: Long-term safety and tolerability. Planned start Feb 2025; status: authorised.
02
Drugs
atacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2024-516380-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516380-81-00.